At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 target
Drug / intervention
My Scrivener(R)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
My Scrivener® - Measuring Effectiveness and Dose Response in Children
In Brief
A Phase 2 clinical trial evaluating My Scrivener(R) for Asperger's Syndrome and 6 related conditions. Completed, enrolled 176 participants across 1 site.
Detailed Summary
This study will assess whether a computer haptic peripheral device programmed to provide repetitive motion training is as effective as the same repetitive motion training provided by a human being.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder, ADHD, Traumatic Brain Injury, Stroke
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJun 2009
Primary CompletionSep 2010
TodayJul 2026
First PostedJun 12, 2009
Enrollment StartApr 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.1 years ago
Interventions
My Scrivener(R)device
Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.